MediPharm Labs (LABS) Competitors C$0.08 0.00 (0.00%) As of 08/28/2025 03:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock LABS vs. HLS, SUGR, TGOD, NINE, WMD, MDP, DB, HEXO, VIR, and ZOMShould you be buying MediPharm Labs stock or one of its competitors? The main competitors of MediPharm Labs include HLS Therapeutics (HLS), SugarBud Craft Growers (SUGR), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), WeedMD (WMD), Medexus Pharmaceuticals (MDP), Decibel Cannabis (DB), HEXO (HEXO), Viridium Pacific Group (VIR), and Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM). These companies are all part of the "drug manufacturers - specialty & generic" industry. MediPharm Labs vs. Its Competitors HLS Therapeutics SugarBud Craft Growers Green Organic Dutchman Delta 9 Cannabis WeedMD Medexus Pharmaceuticals Decibel Cannabis HEXO Viridium Pacific Group Zomedica Pharmaceuticals Corp. (ZOM.V) HLS Therapeutics (TSE:HLS) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings. Is HLS or LABS more profitable? MediPharm Labs has a net margin of -30.56% compared to HLS Therapeutics' net margin of -38.70%. MediPharm Labs' return on equity of -24.41% beat HLS Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HLS Therapeutics-38.70% -25.27% -2.89% MediPharm Labs -30.56%-24.41%-7.17% Do institutionals and insiders believe in HLS or LABS? 65.2% of HLS Therapeutics shares are held by institutional investors. Comparatively, 0.7% of MediPharm Labs shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Comparatively, 4.5% of MediPharm Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, HLS or LABS? HLS Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, MediPharm Labs has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Does the media refer more to HLS or LABS? In the previous week, HLS Therapeutics had 16 more articles in the media than MediPharm Labs. MarketBeat recorded 16 mentions for HLS Therapeutics and 0 mentions for MediPharm Labs. HLS Therapeutics' average media sentiment score of 1.10 beat MediPharm Labs' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media. Company Overall Sentiment HLS Therapeutics Positive MediPharm Labs Neutral Do analysts prefer HLS or LABS? HLS Therapeutics presently has a consensus target price of C$5.00, suggesting a potential downside of 6.54%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe HLS Therapeutics is more favorable than MediPharm Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HLS Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00MediPharm Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, HLS or LABS? MediPharm Labs has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHLS TherapeuticsC$40.13M2.97-C$15.53M-C$1.00-5.36MediPharm LabsC$39.42M0.79-C$12.05M-C$0.03-2.58 SummaryHLS Therapeutics beats MediPharm Labs on 9 of the 15 factors compared between the two stocks. Get MediPharm Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LABS vs. The Competition Export to ExcelMetricMediPharm LabsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$31.13MC$2.18BC$5.78BC$6.40BDividend YieldN/A2.92%3.95%6.72%P/E Ratio-2.584.3131.2666.88Price / Sales0.79645.65431.161,650.19Price / Cash1.3010.3737.7383.29Price / Book0.6811.4310.045.33Net Income-C$12.05MC$20.70BC$3.27BC$301.20M7 Day PerformanceN/A0.92%1.34%2.61%1 Month PerformanceN/A5.46%6.13%4.83%1 Year PerformanceN/A5.15%41.90%32.34% MediPharm Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABSMediPharm LabsN/AC$0.08flatN/A+15.4%C$31.13MC$39.42M-2.58130HLSHLS Therapeutics0.9147 of 5 starsC$5.15-0.2%C$4.50-12.6%+72.6%C$114.58MC$40.13M-5.1691Gap UpSUGRSugarBud Craft GrowersN/AC$13.25-1.8%N/A+66.0%C$90.37MC$575.64M15.9644TGODGreen Organic DutchmanN/AN/AN/AN/AC$89.95MC$31.37M-0.6541Gap UpHigh Trading VolumeNINEDelta 9 CannabisN/AC$1.03+3.0%N/A+0.0%C$89.36MC$12.87M19.07940Gap UpWMDWeedMDN/AC$0.28-1.8%N/A+0.0%C$67.82MC$27.53M-0.66628Gap UpMDPMedexus Pharmaceuticals1.5764 of 5 starsC$2.98+6.0%C$5.49+84.1%+24.4%C$66.72MC$100.25M14.2598Gap UpDBDecibel CannabisN/AC$0.13-7.4%N/A+107.7%C$51.13MC$105.60M-12.5083,000HEXOHEXON/AN/AN/AN/AC$38.72MC$124.10M-0.26690VIRViridium Pacific GroupN/AC$0.38+5.6%N/A+0.0%C$37.52MC$1.09M-2.97580Gap UpZOMZomedica Pharmaceuticals Corp. (ZOM.V)N/AC$0.29-6.6%N/A+0.0%C$36.73MN/A-2.6150Gap Down Related Companies and Tools Related Companies HLS Therapeutics Competitors SugarBud Craft Growers Competitors Green Organic Dutchman Competitors Delta 9 Cannabis Competitors WeedMD Competitors Medexus Pharmaceuticals Competitors Decibel Cannabis Competitors HEXO Competitors Viridium Pacific Group Competitors Zomedica Pharmaceuticals Corp. (ZOM.V) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:LABS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediPharm Labs Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediPharm Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access